KEAP1 and non-small cell lung carcinoma: [20] Since the Keap1-Nrf2 pathway plays as primary regulator of key cellular processes that contribute to resistance against chemotherapy drugs, NRF2 has been studied as a potential therapeutic target molecule in NSCLC and some other cancers.